IVSI - ETF AI Analysis
Top Page
Applied Finance IVS International Large ETF (IVSI)
IVSI, the Applied Finance IVS International Large ETF, appears to be a solid, quality-focused fund, helped by strong holdings like Novartis, AstraZeneca, ASML, and Mitsubishi UFJ, which all show robust financial performance, healthy profitability, and generally supportive technical trends. The rating is held back somewhat by names such as Deutsche Telekom, Allianz, and Recruit Holdings, where bearish or mixed momentum and valuation concerns introduce more risk. A key risk factor for the ETF is its meaningful exposure to a few large international companies, so weakness in these individual stocks or their sectors could have a noticeable impact on the fund.
IVSI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 9.39M
- Region
- Developed Markets
- Expense Ratio
- 0.65%
- Beta
- 0.73
- Issuer
- Applied Finance
- Inception Date
- Dec 11, 2025
- Dividend Yield
- 0.04%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
IVSI Summary
The Applied Finance IVS International Large ETF (IVSI) is an actively managed fund that invests in large companies outside the U.S., mainly in countries like Japan, the UK, and Germany. It doesn’t track a fixed index, but instead uses research to pick individual stocks. The fund holds well-known names such as ASML Holding and Roche, giving investors exposure to global leaders across many sectors. Someone might invest in IVSI to diversify beyond the U.S. and seek long-term growth from international markets. A key risk is that its value can rise or fall with global stock markets and currency swings.
How much will it cost me?
This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, with managers doing in-depth research to pick international large-cap stocks rather than just tracking an index.
What would affect this ETF?
This ETF could benefit if developed markets outside North America grow steadily, especially if demand stays strong for global health care, financial, and technology leaders like ASML, Roche, and AstraZeneca, and if a weaker U.S. dollar makes international stocks more attractive. On the other hand, it could face challenges from slower economic growth in Europe or Japan, tighter global financial conditions, changing regulations affecting banks and drug makers, or a downturn in commodity and luxury goods demand that would hurt holdings like Rio Tinto and LVMH.
IVSI Top 10 Holdings
IVSI leans heavily on a handful of international heavyweights, with chip-equipment giant ASML and Japan’s Recruit Holdings acting as key engines of growth thanks to their rising, tech-driven momentum. Financial names like Mitsubishi UFJ and Allianz are generally supportive, though their performance has been more steady to mixed. On the defensive side, Roche and Novartis provide healthcare ballast but have recently lost a bit of steam, while BHP’s commodity exposure has been choppy. Overall, the fund is diversified across sectors and focused on developed markets outside North America.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.79% | $449.92K | EUR 564.27B | 68.36% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 AU:BHP | BHP Group Ltd | 2.97% | $278.93K | AUD 305.16B | 37.15% | 68Neutral |
 CH:NOVN | Novartis AG | 2.41% | $226.65K | CHF 228.27B | 19.51% | 80Outperform |
 JP:8306 | Mitsubishi UFJ Financial Group | 2.37% | $222.09K | JPY 38.86T | 51.02% | 76Outperform |
 DE:DTE | Deutsche Telekom | 2.22% | $208.52K | EUR 123.82B | -12.65% | 67Neutral |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 DE:ALV | Allianz | 1.65% | $155.20K | EUR 164.32B | 19.20% | 67Neutral |
 JP:6098 | Recruit Holdings Co | 1.57% | $147.30K | JPY 25.01T | 140.91% | 67Neutral |
IVSI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IVSI, the sentiment is Positive. The current price of 29.25 is above the 20-day moving average (MA) of 28.92, below the 50-day MA of 29.48, and above the 200-day MA of 28.15, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of 73.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IVSI.
IVSI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IVSI | $29.26 | $31.00(5.96% Upside) | $9.39M | 0.65% | 67Neutral |
 QUIZ | $28.33 | $33.83(19.44% Upside) | $95.98M | 0.55% | 66Neutral |
 JIDE | $51.15 | $60.34(17.95% Upside) | $28.55M | 0.55% | 68Neutral |
 TACN | $28.30 | $33.58(18.65% Upside) | $24.06M | 0.00% | 66Neutral |
 ENHI | $26.57 | $32.32(21.64% Upside) | $21.28M | 0.27% | 65Neutral |
 IVSX | $25.81 | ― | $4.86M | 0.75% | 59Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IVSI | Applied Finance IVS International Large ETF | 29.25 | 3.68 | 14.40% | |
| QUIZ | Zacks Quality International ETF | 28.32 | 2.82 | 11.05% | |
| JIDE | JPMorgan International Dynamic ETF | 51.15 | 1.83 | 3.72% | |
| TACN | T. Rowe Price Active Core International Equity ETF | 28.30 | 3.07 | 12.15% | |
| ENHI | iShares Enhanced International Active ETF | 26.57 | 2.33 | 9.61% | |
| IVSX | Applied Finance IVS International SMID ETF | 25.81 | 0.52 | 2.08% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.